LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4243 | 4245 | 0.9980 | 0.9959 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4244 | 4245 | 0.9994 | 0.9990 |
| SK-BR-3 | Ruxolitinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4275 | 4245 | 1.0070 | 1.0083 |
| SK-BR-3 | Ruxolitinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4115 | 4245 | 0.9708 | 0.9643 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 4351 | 4245 | 1.0262 | 1.0335 |
| SK-BR-3 | Ruxolitinib | 10 | uM | LJP5 | 72 | hr | 1401 | 3908 | 4245 | 0.9232 | 0.9040 |
| SK-BR-3 | Momelotinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4164 | 4245 | 0.9810 | 0.9762 |
| SK-BR-3 | Momelotinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4144 | 4245 | 0.9762 | 0.9701 |
| SK-BR-3 | Momelotinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 3946 | 4245 | 0.9304 | 0.9123 |
| SK-BR-3 | Momelotinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3527 | 4245 | 0.8315 | 0.7820 |
| SK-BR-3 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 2884 | 4245 | 0.6790 | 0.5679 |
| SK-BR-3 | Momelotinib | 10 | uM | LJP5 | 72 | hr | 1401 | 1632 | 4245 | 0.3846 | 0.0982 |
| SK-BR-3 | Fedratinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4485 | 4245 | 1.0586 | 1.0748 |
| SK-BR-3 | Fedratinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4226 | 4245 | 0.9954 | 0.9942 |
| SK-BR-3 | Fedratinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 3870 | 4245 | 0.9120 | 0.8880 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3441 | 4245 | 0.8119 | 0.7560 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 2865 | 4245 | 0.6741 | 0.5607 |
| SK-BR-3 | Fedratinib | 10 | uM | LJP5 | 72 | hr | 1401 | 1116 | 4245 | 0.2622 | -0.1372 |
| SK-BR-3 | Trametinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3281 | 4245 | 0.7708 | 0.6957 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3265 | 4245 | 0.7672 | 0.6913 |
| SK-BR-3 | Trametinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 3373 | 4245 | 0.7937 | 0.7290 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3405 | 4245 | 0.7996 | 0.7349 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3487 | 4245 | 0.8197 | 0.7633 |
| SK-BR-3 | Trametinib | 10 | uM | LJP5 | 72 | hr | 1401 | 3614 | 4245 | 0.8500 | 0.8045 |
| SK-BR-3 | Omipalisib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1406 | 4168 | 0.3373 | 0.0018 |